Immune Response in Peripheral Blood of Patients With Colon Cancer

University of Arizona

Status

Completed

Conditions

Colorectal Cancer

Treatments

Other: immunoenzyme technique

Other: laboratory biomarker analysis

Study type

Observational

Funder types

Other

NIH

Identifiers

NCT00900432

P30CA023074 (U.S. NIH Grant/Contract)

04-0331-01

UARIZ-04-81 (Other Identifier)

P50CA095060 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that may occur in the immune system that may help kill cancer cells.

PURPOSE: This laboratory study is looking at anticancer immune responses in the peripheral blood of patients with colon cancer.

Full description

OBJECTIVES:

Quantify T cells specific for tumor peptides (carcinoembryonic antigen and MUC1) from the peripheral blood of patients with colon cancer.

OUTLINE: This is an open-label study.

Patients undergo blood collection at time of follow-up, surgery, thoracentesis, paracentesis, or leukapheresis (≤ 5 times per year). Blood is analyzed for tumor peptides (carcinoembryonic antigen and MUC1), circulating cytokines, and lymphocyte response by ELISA, ELISPOT, or intracellular flow.

PROJECTED ACCRUAL: A total of 140 patients will be accrued for this study.

Enrollment

67 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS: